Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 25, 2018 -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S. financial markets on Wednesday, May 2, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2018 to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 1088768.
About Immune Design
Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex® and GLAAS®. Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
Media Contact
Julie Rathbun
[email protected]
206-769-9219
Investor Contact
Sylvia Wheeler
[email protected]
